From GlobeNewswire: 2025-03-20 16:05:00

SELLAS Life Sciences Group, Inc. reported positive outcomes from its Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML. The trial is progressing well, with the final analysis expected in 2025. Additionally, positive data from the Phase 2 Trial of SLS009 in r/r AML was shared, with full data and FDA feedback anticipated in 1H 2025.

In January 2025, SELLAS raised $25 million in gross proceeds through a registered direct offering, strengthening its financial position. The company remains focused on advancing its key assets through clinical development, with promising results from ongoing trials.

Financial results for the full year 2024 showed research and development expenses of $19.1 million and general and administrative expenses of $12.4 million. The net loss for the year was $30.9 million, with cash and cash equivalents totaling approximately $13.9 million as of December 31, 2024.

SELLAS continues to drive innovation in cancer therapeutics, with a focus on developing novel treatments. Regulatory designations for its programs, including FDA Rare Pediatric Disease Designations and EMA Orphan Drug Designations, highlight the potential impact of its therapies. The company is committed to delivering value to patients and shareholders through its pipeline advancements.



Read more at GlobeNewswire:: SELLAS Life Sciences Reports Full Year 2024 Financial